Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Cortex has reported net loss of $984,000 or $0.01 loss per diluted share for the fourth quarter ended 31 December 2010, compared to net loss of $1.6m, or $0.02 loss per diluted share for the comparable period in 2009.
Subscribe to our email newsletter
Cortex is a neuroscience company engaged in novel drug therapies for treating psychiatric disorders, neurological diseases and sleep apnea.
The company has posted loss from operations of $986,000, compared to $1.47m for the comparable period in 2009.
For the full year ended 31 December 2010, the company has posted a net income of $1.63m, or $0.02 per diluted share, compared to net loss of $8.44m, or $0.19 per diluted share, for the year ago period.
Cortex has reported its income from operations of $2.18m, compared to loss from operations of $8.34m for the year ago period.